MK-571

MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release[1][2][3].

Product Specifications

CAS Number

[115104-28-4]

Product Name Alternative

L-660711

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Leukotriene Receptor; LPL Receptor; P-glycoprotein

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/MK-571.html

Concentration

10mM

Purity

98.85

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O

Molecular Formula

C26H27ClN2O3S2

Molecular Weight

515.09

Precautions

H302, H315, H319, H335

References & Citations

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

LTD4/CysLT1; LTE4

Citation 01

3 Biotech. 2025 Apr;15 (4) :72.|Adv Sci (Weinh) . 2025 Aug 4:e04680.|Biomed Pharmacother. 2020 Sep;129:110506.|Cell Death Discov. 2024 Aug 14;10 (1) :364.|Drug Metab Dispos. 2025 Sep 24.|J Drug Deliv Sci Technol. 2025 May.|J Pharm Biomed Anal. 2020 Sep 10;189:113441.|Nat Commun. 2023 Sep 19;14 (1) :5709.|Toxicology. 2025 Jun 3:154210.|Viruses. 2019 Apr 24;11 (4) :378.|Arch Toxicol. 2020 Nov;94 (11) :3799-3817.|Biomed Pharmacother. 2018 Oct:106:1563-1569.|Brain Res Bull. 2022 Oct 15:189:69-79.|Cancer Res Commun. 2024 Apr 9;4 (4) :1024-1040.|Cell. 2023 Dec 7;186 (25) :5500-5516.e21.|CNS Neurosci Ther. 2023 Jan;29 (1) :445-457.|Commun Biol. 2024 May 23;7 (1) :621.|Eberhard Karls Universität Tübingen. 2022 Feb.|Eur J Drug Metab Pharmacokinet. 2022 Mar;47 (2) :279-289.|Eur J Drug Metab Pharmacokinet. 2024 Sep;49 (5) :609-617.|Eur J Pharm Sci. 2023 May 1:184:106414.|Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Int J Nanomedicine. 2019 Nov 27;14:9217-9234.|J Appl Toxicol. 2024 Nov;44 (11) :1725-1741.|Pharmaceutics. 2024 May 29;16 (6) :731.|Pharmacol Res Perspect. 2022 Feb;10 (1) :e00928.|Regul Toxicol Pharmacol. 2019 Nov:108:104449.|Sci Adv. 2024 Dec 13;10 (50) :eadq4274.|Toxicol Lett. 2020 Jul 1;327:9-18.|Xenobiotica. 2020 Mar;50 (3) :354-362.